CGH
FLGT icon

Crossmark Global Holdings’s Fulgent Genetics FLGT Stock Holding History

Crossmark Global Holdings’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,710
Closed -$1.32M – 1406
2021
Q3 		$1.32M Sell
14,710
-730
-5% -$66.3K 0.03% 519
2021
Q2 		$1.42M Sell
15,440
-200
-1% -$16K 0.03% 492
2021
Q1 		$1.51M Buy
15,640
+710
+5% +$73.3K 0.04% 457
2020
Q4 		$778K Buy
+14,930
New +$624K 0.02% 654

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Crossmark Global Holdings's FLGT Position: Q4 2021 in Review

Crossmark Global Holdings sold out of Fulgent Genetics (FLGT) in Q4 2021, closing a stake of 14,710 shares — an estimated $1.32M sold.

Crossmark Global Holdings first reported a position in FLGT in Q4 2020 and held it in 4 quarters. The position peaked at $1.51M in Q1 2021. 299 funds tracked by Wall St. Rank hold FLGT as of Q4 2021.

  • Crossmark Global Holdings reported no remaining Fulgent Genetics position as of Q4 2021 after selling out during the quarter.
  • Crossmark Global Holdings sold 14,710 Fulgent Genetics shares in Q4 2021, an estimated $1.32M.
  • Crossmark Global Holdings first reported a position in Fulgent Genetics in Q4 2020 and held it in 4 quarters.
  • Crossmark Global Holdings's Fulgent Genetics position peaked at $1.51M in Q1 2021.
  • 299 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2021.

Based on Crossmark Global Holdings's 13F filing for Q4 2021, filed 10 Jan 2022.